MetaCap

Moderna Inc. (MRNA)

NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

195.00-4.33 (-2.17%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MRNA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$78.90B
EPS (TTM)
-$7.04
52-week range
23.55 – 280.80
Day range
191.46 – 210.00
Volume / Avg
9.66M / 16.52M
Beta
—

52-week range

$23.55$280.80

MRNA stock today

Shares of Moderna (MRNA) finished lower on Nov 20 at $195.00, a drop of 2.17% or $4.33 per share, versus the S&P 500's 3.70% decline. At this level, MRNA sits in the middle of its 52-week range of $23.55 to $280.80: 30.6% below the high, set on Nov 9, 2026 and 728.2% above the low. MRNA is up 561.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 722.1%.

Moderna has posted a net loss over the last twelve months (EPS of -$7.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Moderna

Company profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Stéphane Bancel M.B.A.
Headquarters
Cambridge, MA
Employees
4,700
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Moderna generated $1.94 billion in revenue, down 39.9% from fiscal 2024, its first annual decline since 2024. Moderna reported a net loss of $2.82 billion, compared with a loss of $3.56 billion a year earlier. Gross margin was 55.3% (up from 54.8%) and operating margin -158.1%.

Moderna annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.94B$3.24B$6.85B$19.26B$18.47B
Growth-39.93%-52.75%-64.45%+4.29%+2200.25%
Net income$-2.82B$-3.56B$-4.71B$8.36B$12.20B
EPS (diluted)$-7.26$-9.28$-12.33$20.12$28.29

Analyst forecast

Forecast

Consensus (23 analysts)

hold

Avg. price target

$165.32-15.22%

  • Strong buy 1
  • Buy 3
  • Hold 16
  • Sell 2
  • Strong sell 1

Target range

Low $45.00High $305.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$0.38 vs $-1.10
Surprise
+134.55%

MRNA news

All MRNA news

Moderna peers

Health Care sector
MRNA peer companies
CompanyPrice% ChgMarket capCompare
ARGXargenx SE ADR925.70-1.73%$58.21Bvs MRNA
BIIBBiogen Inc.249.59+1.00%$36.89Bvs MRNA
RVMDRevolution Medicines Inc.161.20+1.11%$34.87Bvs MRNA
BNTXBioNTech SE ADR80.96-0.52%$20.07Bvs MRNA
EXELExelixis Inc.64.63-1.82%$15.77Bvs MRNA
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs MRNA
TECHBio-Techne Corp72.67-0.04%$11.42Bvs MRNA
RGENRepligen Corporation163.81-3.81%$10.47Bvs MRNA

Indexes, lists and sector

Moderna stock FAQ

What is Moderna's stock price today?

MRNA last traded at $195.00 as of Nov 20, 4:00 PM EST, down 2.17% on the day. Prices are delayed at least 15 minutes.

Is Moderna in the S&P 500?

Yes. Moderna (MRNA) is a constituent of the S&P 500 index.

Who is Moderna's CEO?

Mr. Stéphane Bancel M.B.A. is the chief executive officer of Moderna Inc., which has about 4,700 employees.

What is the MRNA 52-week high?

The 52-week high for MRNA is $280.80 and the 52-week low is $23.55. The stock is currently 30.6% below its high.

Compare MRNA